Logo-bi
Bioimpacts. 2023;13(6): 439-455. doi: 10.34172/bi.2023.27521
PMID: 38022382        PMCID: PMC10676524

Review

The application, safety, and future of ex vivo immune cell therapies and prognosis in different malignancies

Katelyn R. Einloth 1 ORCID, Scott Gayfield 1, Thomas McMaster 1, Alexander Didier 1, Lance Dworkin 1, Justin Fortune Creeden 2,3 * ORCID

Cited by CrossRef: 1


1- Patz E, Gottlin E, Simon G. Perspective: rethinking therapeutic strategies in oncology. Front Oncol. 2024;13 [Crossref]


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2024): 20% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMedPubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science IndicatorsEmbase; EBSCOhost; CAS: DOAJSHERPA/RoMEO
Member of COPE
Follower of ICMJE
Permission: Creative Commons